Raniclor

Quick links to important sections

Raniclor

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Raniclor

Quick Facts Description
Active ingredient Cefaclor
Form Capsule, Oral Suspension, Extended-release Tablet
Pharmacological class Second-generation Cephalosporin Antibiotic
Common use Anti-infective / Anti-bacterial agent
Origin Semisynthetic

Raniclor is a pharmaceutical product primarily defined by its single active ingredient, cefaclor, which is classified as a potent anti-infective agent. The active compound, with the chemical formula C15H14ClN3O4S, is a semisynthetic substance. This means it is manufactured by chemically modifying a naturally derived nucleus. This single-ingredient medicine is designed for oral administration and is often clinically recognized for its versatility in treating susceptible bacterial infections. Raniclor is available in several distinct dosage forms, including the standard capsule, oral suspension (liquid) which is frequently preferred for pediatric or elderly patient groups, and a specialized extended-release tablet.

Raniclor's Classification as a Second-Generation Cephalosporin

Raniclor's active component, cefaclor, belongs to the cephalosporin antibiotics pharmacological class. More specifically, it is categorized as a second-generation cephalosporin, a grouping defined by its molecular structure. This classification is vital because it places cefaclor within the beta-lactam family, but its secondary generation status provides a broader spectrum of activity compared to agents in the first generation. Cefaclor’s properties are frequently compared to other second-generation cephalosporins during therapeutic planning.

General Purpose and Bactericidal Function of Raniclor

The general purpose of Raniclor is to help the body effectively counter bacterial illnesses by acting as a bactericidal agent. Bactericidal action is a fundamental function of many antibiotics wherein the compound actively works to kill susceptible microorganisms rather than merely inhibiting their reproduction. This mechanism makes cefaclor effective against susceptible bacteria by disrupting cell wall synthesis. This action on bacteria serves as the core therapeutic anti-bacterial agent function, halting the spread and growth of bacteria to assist in resolving the underlying infection.

What side effects are possible with Raniclor?

Possible side effects and safety information

The safety profile of Raniclor (cefaclor) is organized and communicated through frequency classifications and affected body systems, as documented in official regulatory sources. Adverse reactions are grouped by the physiological system they affect, including Gastrointestinal, Blood and the Lymphatic System, Immune System, and Nervous System Disorders.

Common adverse reactions (occurring in ge 1/100 to <1/10 patients) frequently involve the digestive tract and skin. These include diarrhoea, nausea, vomiting, abdominal discomfort, headache, pruritus (itching), urticaria (hives), and morbilliform eruptions (a type of rash).

Serious Adverse Reactions are explicitly documented, often classified with a Frequency Not Known or Rare designation. These include severe immediate allergic responses such as Anaphylaxis, serious cutaneous reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), Pseudomembranous colitis, and hematological disorders such as Hemolytic anaemia and Agranulocytosis.

Time- and population-related safety patterns are also noted in official labeling. Serum sickness-like reactions are reported more frequently in pediatric patients and may develop during or following a second course of therapy. Symptoms of Pseudomembranous colitis may occur during treatment or persist for two months or more following discontinuation. Caution is noted regarding increased risk of neurotoxicity, including seizures, in patients with renal impairment. The medication may also interfere with certain laboratory tests, potentially causing false-positive results for urine glucose using copper sulfate methods.

Overdose and Emergency Response

Raniclor Overdose and When to Seek Help

The official regulatory documentation for Raniclor (Cefaclor) overdose primarily describes gastrointestinal symptoms and the potential for severe systemic effects. Manifestations may include nausea, vomiting, epigastric distress, and diarrhea. More serious outcomes involve the Central Nervous System (CNS), where convulsions or seizures are listed as potential severe effects, particularly in patients with existing renal impairment.

Regulatory Mandate for Emergency Action

The regulatory guidance clearly states that if an overdose is suspected, immediate medical attention must be sought. Individuals must immediately call emergency services if the person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. Hospital monitoring and observation of the patient are required for management.

Official Management Approach

Official labeling states that no specific antidote is known for Cefaclor overdose. Consequently, treatment is strictly symptomatic and supportive, focusing on general care. For recent ingestions of a large amount, procedures such as gastric lavage and the use of activated charcoal may be considered. Hemodialysis is documented to shorten the serum half-life, though its overall efficacy in overdose clearance is limited. Special consideration is given to pediatric overdose cases, where transient hematuria and proteinuria have been observed.

Therapeutic Uses of Raniclor

What Raniclor Treats: Main Uses and Benefits

Raniclor (Cefaclor) is commonly used to help manage bacterial infections across several major body systems. It is considered relevant in clinical contexts where short-term symptomatic assistance is needed.


Therapeutic Focus and Symptom Support

The medication is used across conditions characterized by periods of heightened symptoms, relevant to therapeutic domains including infections of the lower and upper respiratory tracts (e.g., pneumonia, sinusitis, acute bacterial exacerbations of chronic bronchitis), otitis media (ear infection), pharyngitis/tonsillitis, urinary tract infections, and uncomplicated skin and soft-tissue infections.

Raniclor is relevant for managing symptoms that interfere with daily comfort and may become intense or disruptive, such as fever, localized pain, and inflammation. In these acute clinical scenarios, the medicine contributes to easing the overall symptom load.

“It provides supportive relief when symptoms related to inflammatory or irritative states, such as painful urination or ear pain, interfere with routine activities.”

Quick Fact Description
Symptom Axis Symptoms related to inflammatory or irritative states
Condition Frame Conditions characterized by periods of heightened symptoms

It is applied in scenarios where additional management of discomfort is required, helping maintain a sense of stability and supporting general well-being during symptomatic phases when symptoms are more noticeable.

Regulatory References

  1. U.S. National Library of Medicine (NIH) DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Raniclor (Cefaclor) — Official Regulatory Information


Eligibility Scope

Classification Population or Condition Regulatory Status
Contraindicated Known allergy/hypersensitivity to cefaclor or any other cephalosporin antibiotic. Absolute exclusion.
Use Not Established Infants less than one month of age. Safety and efficacy have not been determined.
Use Not Established Children younger than 16 years (for the extended-release tablet formulation only). Safety and efficacy have not been determined.
Conditional Use (Caution) Patients with a history of penicillin allergy. Caution advised due to documented beta-lactam cross-hypersensitivity.
Conditional Use (Caution) Patients with markedly impaired renal function. Caution required; careful clinical observation is mandated.
Conditional Use (Caution) Individuals with a history of gastrointestinal disease, particularly colitis. Caution required due to documented risk of CDAD (Clostridioides difficile-associated diarrhea).
Conditional Use (Caution) Pregnant women. Use only if clearly needed; classified as Pregnancy Category B.
Conditional Use (Caution) Nursing (breastfeeding) women. Caution is advised; small amounts of cefaclor are detected in breast milk.

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility by requiring absolute exclusion based on drug class allergy (cephalosporins) and establishing minimum age thresholds for use. The profile imposes mandatory conditional use requirements when prescribing to populations with compromised renal function or a history of colitis, or in cases of documented cross-allergy to penicillin. These classifications strictly delineate the patient groups permitted, restricted, or prohibited from using the medicine according to governmental labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Raniclor (Cefaclor), primarily involving pharmacokinetic and pharmacodynamic mechanisms as outlined in government-approved labeling.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Outcome (Regulatory Description)
Probenecid Increases and prolongs the serum concentration of Cefaclor by inhibiting its renal tubular secretion.
Oral Anticoagulants (e.g., Warfarin) Potentiation of the anticoagulant effect, which is documented to increase the risk of bleeding.
Oral Contraceptives Cefaclor may cause a documented reduction in the effectiveness of oral contraceptives by altering intestinal bacterial flora.

Form-Specific Administration Constraints

Interactions with food vary by formulation. The use of immediate-release forms with food results in a significant reduction (50% to 75%) of the peak plasma concentration ( Cmax), though total absorption remains unchanged. Conversely, the extended-release tablets must be administered with meals to ensure enhanced absorption. Furthermore, to maintain the product's intended release profile, extended-release tablets are restricted from being cut, crushed, or chewed.

Population Considerations

In patients with renal impairment, the half-life of Cefaclor may be slightly prolonged, which is a consideration related to potential exposure modification.

Mechanism of Action

The activity of Raniclor is driven by the selective inhibition of bacterial cell wall synthesis, mediated by its active ingredient, Cefaclor. This action results in microbial death via a bactericidal mechanism. The mechanism begins with Cefaclor acting as an irreversible covalent inhibitor of bacterial enzymes known as penicillin-binding proteins (PBPs). These PBPs are transpeptidases necessary for the cross-linking of peptidoglycan chains, which form the rigid scaffolding of the cell wall. The irreversible binding occupies the PBP active sites, permanently arresting the final stage of cell wall assembly in susceptible bacteria. This failure to correctly construct the cell wall triggers the dysregulated activation of bacterial autolytic enzymes. This cascade causes the bacterial cell to lose its osmotic integrity, resulting in immediate cellular lysis (rupture). This mechanistic sequence establishes the definitive bactericidal physiological effect. The mechanism is functionally constrained by bacterial defense, primarily the production of beta-lactamase enzymes that chemically hydrolyze the drug's beta-lactam ring, or by mutated PBPs that reduce binding affinity, thereby protecting the target enzyme.

Dosage and Administration Information

Raniclor (cefaclor) is administered exclusively via the oral route, available as an immediate-release capsule or suspension and an extended-release tablet. The administration pattern adheres to specific dosage frequencies and conditions.

The standard adult dose for the immediate-release formulation is 250 mg taken every eight hours. For managing more severe conditions, the dosage may be increased to 500 mg every eight hours, although the total daily intake must not exceed 4 grams. In contrast, the extended-release tablet is prescribed for administration on a twice-daily (every 12 hours) schedule.

Specific timing related to meals depends on the formulation used. Immediate-release capsules and suspensions may be taken with or without food. However, the extended-release tablets must be administered with meals or within one hour of eating to ensure proper absorption. Due to its formulation, the extended-release tablet is designed to be swallowed whole and must not be cut, crushed, or chewed. The oral suspension must be shaken well before each dose.

Regarding the course of use, therapy is typically maintained for at least 48 to 72 hours after the patient becomes asymptomatic. Specifically, treatment for infections caused by beta-haemolytic streptococci must be completed for a minimum duration of 10 days. Dosage adjustments for pediatric patients (typically based on 20 mg/kg/day) and haemodialysis patients are also specified.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of [Drug X] Research

Research has evaluated the effect of [Drug X] in the treatment of [Condition Y] and its symptoms. Studies have examined whether it might reduce the severity and duration of [Condition Y] episodes, investigating a reduction in patient symptoms.

Research has evaluated the effects of starting treatment as soon as symptoms begin.

Key Study Findings

Randomized Controlled Trials (RCTs)

A number of RCTs have been conducted across different adult populations.

  • Efficacy vs. Placebo: Research has explored whether [Drug X] is associated with a shorter duration of symptoms compared to a placebo.
  • Dose Response: Trials have investigated the relationship between different dosing schedules and the severity of reported side effects.
  • Comparative Effects: Studies have also examined the effects of [Drug X] when used alongside [Treatment B] to see whether this relates to different patient outcomes.

Post-Market Surveillance and Observational Data

Studies have investigated the effects and tolerability of [Drug X] in adults. Large-scale observational studies have investigated whether this drug is associated with an improvement in the quality of life (QoL) for users. Further research has investigated the long-term safety profile of the treatment.

  • Specific Populations: Studies have been conducted to evaluate the treatment’s use in adolescents and in older adults with [Co-morbidity A].

Meta-Analyses and Systematic Reviews

A recent meta-analysis included studies comparing the drug to older treatments. Researchers continue to investigate the use of [Drug X] alongside alternative therapies across diverse patient groups. Research has been conducted to evaluate its use within care settings.

Frequently Asked Questions (FAQ)

Common questions about Raniclor (FAQ)

Q: Is Raniclor the same kind of medication as Zantac or Pepcid?

A: Raniclor is classified as a second-generation cephalosporin antibiotic, and its primary purpose is to treat bacterial infections. Medications like Zantac (ranitidine) or Pepcid (famotidine) are used to reduce stomach acid. According to official labeling, Raniclor is an anti-bacterial agent, not an acid-reducing drug.

Q: Why would a doctor choose Raniclor instead of over-the-counter acid reducers?

A: Raniclor is fundamentally different from acid reducers because it is an antibiotic prescribed to fight bacterial infections, not heartburn. The active ingredient, Cefaclor, works by killing susceptible bacteria. Acid reducers only address symptoms of excess acid and cannot treat a bacterial illness.

Q: What are the most common side effects people report when taking Raniclor?

A: Official product information notes that common side effects are often referred to as 'common' in clinical reporting. These frequently include issues like diarrhea, nausea, vomiting, abdominal discomfort, and headache. Skin reactions such as pruritus (itching) and rashes may also occur.

Q: Can taking Raniclor upset my stomach or cause diarrhea?

A: Yes, digestive issues are among the common adverse reactions reported in clinical trials. These often include diarrhea, nausea, vomiting, and abdominal discomfort. If these symptoms are a concern, consult a healthcare professional for guidance.

Q: Can I take Raniclor with my blood pressure medication?

A: Official labeling identifies interactions with certain drugs, such as blood thinners like warfarin. While not all blood pressure medications are listed in the official documents, patients should always review their full medication list with a healthcare provider to understand potential interactions.

Q: Does Raniclor interact with common pain relievers like ibuprofen?

A: Official regulatory documents do not list common pain relievers like ibuprofen (a non-steroidal anti-inflammatory drug) as a direct interacting substance. Patients are generally advised to disclose all medications, including over-the-counter pain relievers, to their prescribing physician.

Q: What foods should I avoid when I'm on a Raniclor treatment plan?

A: Official product information does not mandate the avoidance of specific foods while taking Raniclor. However, it does specify that the immediate-release form can be taken with or without food, while the extended-release tablet must be taken with meals to ensure proper absorption.

Q: What happens if I accidentally miss a dose of Raniclor?

A: If a dose is missed, regulatory guidance is generally to take it as soon as you remember. If it is nearly time for your next scheduled dose, you should skip the missed dose and resume your regular dosing schedule. Official guidance usually states that double doses should be avoided.

Q: Is it normal to feel tired when first starting Raniclor?

A: Regulatory documents mention that some central nervous system effects are reported rarely. These include somnolence (drowsiness) and dizziness. If unexpected or persistent tiredness occurs, consulting a healthcare professional is appropriate.

Q: Can I take an antacid at the same time as Raniclor?

A: The official product labeling identifies interactions with certain prescription drugs and food but does not list antacids as a mandatory specific interaction to avoid. It is best practice to consult a healthcare professional regarding the concurrent use of any antacids.

Q: Can Raniclor interact with birth control pills?

A: Yes, official regulatory documentation states that Cefaclor, the active ingredient, may cause a documented reduction in the effectiveness of oral contraceptives (birth control pills) by altering intestinal bacterial flora.

Q: Is Raniclor available as a generic drug?

A: Yes, the active ingredient in Raniclor, which is Cefaclor, is widely available in a generic form. Generic versions are required to contain the same active medicinal ingredients as the brand name product.

Q: Can Raniclor lose its effectiveness over time?

A: Official information discusses the potential for bacteria to develop resistance to Cefaclor. For this reason, it is emphasized that the medicine should only be used for infections confirmed or strongly suspected to be caused by susceptible bacteria.

Q: Is Raniclor known to interact with herbal supplements like St. John's Wort?

A: While the official drug label does not specifically list St. John's Wort, some general clinical references for cephalosporins suggest that herbal supplements may potentially interfere with antibiotic efficacy. Patients are generally advised to review all supplements with a healthcare professional.

Q: Are there any warnings about driving or operating machinery while on Raniclor?

A: Central nervous system adverse reactions, such as dizziness and confusion, have been reported rarely in official documents. Patients experiencing these effects should consider how they may affect the ability to safely drive or operate machinery.

Q: What kind of research has been done on the long-term safety of Raniclor?

A: Post-market surveillance studies have investigated the drug's effects and tolerability. Official information notes that some adverse reactions, like severe diarrhea, can occur months after treatment is stopped. Long-term use of any antibiotic also increases the risk of superinfection by non-susceptible organisms.

Q: Where can I find reliable studies about the effectiveness of Raniclor?

A: The official drug labeling and regulatory documents reference the clinical studies, including randomized controlled trials, that were used to establish the efficacy and indications for Raniclor’s approved uses.

Q: Why do some people take Raniclor for conditions that don't seem like stomach issues?

A: Raniclor is an antibiotic used to treat bacterial infections in multiple areas of the body. Official indications include respiratory tract infections, skin and soft tissue infections, and urinary tract infections, not just conditions related to the stomach.

Q: Does Raniclor have any known effects on kidney or liver function?

A: Official reports note that rare adverse reactions affecting the liver and kidneys have occurred. These include transient hepatitis (liver inflammation) and reversible interstitial nephritis (kidney inflammation), as well as slight, temporary changes in lab values related to these organs.

Q: Is there a maximum recommended time frame for using Raniclor?

A: Regulatory information specifies that therapy is generally maintained for a short course, such as 7 to 10 days, or until the patient has been without symptoms for 48 to 72 hours. Antibiotics are generally not intended for indefinite or routine long-term use.

Q: What should I do if Raniclor doesn't seem to be helping my heartburn?

A: Raniclor is an antibiotic prescribed to treat bacterial infections, and it is not indicated for treating heartburn or acid reflux. If you are experiencing heartburn, this is a separate condition that requires its own specific management.

Q: Do people often experience headaches when starting Raniclor?

A: Headache is listed in official documentation as a common adverse reaction, meaning it is seen in a significant number of patients. A persistent or severe headache is a symptom that may warrant consulting a healthcare professional.

Q: Does Raniclor help with H. pylori infections?

A: While Raniclor is a broad-spectrum antibiotic, it is not typically listed as a standard first-line treatment for H. pylori infections. Treatment for this specific bacteria usually involves a combination of other antibiotic agents.

Q: Is it safe to stop taking Raniclor suddenly?

A: Patient instructions emphasize that the full course of antibiotic therapy should be completed as prescribed, even if the patient begins to feel better. Stopping treatment early can lead to the infection returning and may contribute to antibiotic resistance.

Q: Can Raniclor cause changes in mood or anxiety?

A: Official adverse reaction reports occasionally mention central nervous system effects such as agitation and confusion. However, specific changes in mood or anxiety are not explicitly listed in the regulatory documents.

Q: Is Raniclor a common treatment in the U.K. or E.U.?

A: Yes, the active ingredient, Cefaclor, is approved and used in countries within the European Union, with regulatory documents available from national agencies, such as the HPRA in Ireland.

Q: Why do some forums mention Raniclor in discussions about chronic cough?

A: Raniclor is indicated for the treatment of bacterial lower respiratory tract infections, which can sometimes manifest as a chronic cough, particularly during acute exacerbations of conditions like chronic bronchitis.

Q: Does Raniclor affect the results of any common lab tests?

A: Official product information warns that Raniclor may cause a false-positive result when using certain copper sulfate methods for testing urine glucose (sugar) levels.

Q: Is Raniclor considered a prescription-only medicine everywhere?

A: In jurisdictions governed by major regulatory bodies, Raniclor is classified as a prescription-only medicine (Rx Only). It is generally not available without a valid prescription from a licensed healthcare professional.

Q: Can Raniclor be taken with food, or should it be on an empty stomach?

A: This depends on the specific type of Raniclor being used. Immediate-release capsules and suspension can be taken with or without food. However, extended-release tablets must be taken with meals or within one hour of eating.

Q: What is the difference between Raniclor tablets and capsules?

A: Raniclor is available in immediate-release capsules and specialized extended-release tablets. The extended-release form is designed to release the medication slowly over time and has different administration requirements than the immediate-release capsule.

Q: Does Raniclor help with acid reflux at night?

A: Raniclor is an antibiotic used to eliminate bacterial infections and is not indicated for treating acid reflux or heartburn, regardless of the time of day.

Q: Are there any documented cases of long-term problems from using Raniclor?

A: Post-marketing surveillance has documented the occurrence of severe, sometimes delayed, adverse reactions like severe colitis or serious skin conditions. As with most antibiotics, Raniclor is generally reserved for short courses of therapy to treat acute infections.

How should Raniclor be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines specific storage conditions for Raniclor (Cefaclor) based on its form.

Dosage Form Required Storage Condition
Capsules/Tablets Store at controlled room temperature (20 C to 25 C), protected from excessive heat and moisture.
Reconstituted Liquid Must be refrigerated (2 C to 8 C). Do not freeze.

The oral suspension, once mixed, has a limited stability period and must be discarded after 14 days of refrigeration. All dosage forms must be kept in a tightly closed container and stored out of the sight and reach of children.

Disposal of unused or expired medication should follow local regulations or community drug take-back programs. If no take-back option is available, the product can be discarded with household trash after being mixed with an undesirable substance, as it is not on the FDA's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Raniclor found in:

A-Z Index: